ClinicalTrials.gg
CompletedNCT00789477DA VINCIUpdated Sep 9, 2014Results posted

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

A Phase 2 interventional study of Laser Photocoagulation and Intravitreal Aflibercept Injection in Diabetic Macular Edema, sponsored by Regeneron Pharmaceuticals. Completed at 47 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-09.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
10th of 53
221 · median 49
Started
2008
the only one that year
Phase 2
7 of 53
none open now
Registered
2nd of 53
by date
Lead sponsor
6 of 53
Regeneron Pharmaceuticals

Among the 53 studies testing aflibercept in Macular Edema, this one is the 10th largest by enrollment, is the only one that started in 2008, is one of 7 in phase 2, and was the 2nd registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

This is a Phase 2, doubled-masked, randomized study of the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in subjects with diabetic macular edema (DME). Approximately 200 subjects will be randomized in the US, Canada, Australia and EU.

Read the detailed description

Qualified subjects will be randomized to one of 5 treatment arms. The active (treatment) phase of the study will be 52 weeks, with a 6 month safety follow-up

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with DME with central involvement
  • Adults 18 years or older with type 1 or 2 diabetes mellitus with diabetic macular edema
  • ETDRS BCVA: 20/40 to 20/320 (letter score of 73 to 24) in the study eye

Exclusion criteria

Exclusion Criteria:

  • History of vitreoretinal surgery in the study eye
  • Panretinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of screening
  • Previous use of intraocular or periocular in the study eye within 3 months of screening
  • Previous treatment with anti-angiogenic drugs in either eye (pegaptanib sodium, anecortave acetate, bevacizumab, ranibizumab, etc) within 3 months of screening
  • Uncontrolled diabetes mellitus
  • Uncontrolled hypertension defined as systolic > 180mmHg or > 160 mmHg on 2 consecutive measurements or diastolic > 100 mmHg on optimal medical regimen
  • Ocular disorders in the study eye, other than DME, that may confound interpretation of study results
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    Intravitreal Aflibercept Injection .5Q4

    Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) .5 mg every 4 weeks

    Drug: Intravitreal Aflibercept Injection

  • Experimental
    Intravitreal Aflibercept Injection 2Q4

    Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2 mg every 4 weeks

    Drug: Intravitreal Aflibercept Injection

  • Experimental
    Intravitreal Aflibercept Injection 2Q8

    Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by every 8 weeks

    Drug: Intravitreal Aflibercept Injection

  • Experimental
    Intravitreal Aflibercept Injection 2PRN

    Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by PRN (as-needed) dosing according to the re-treatment criteria

    Drug: Intravitreal Aflibercept Injection

  • Active comparator
    Laser Photocoagulation

    Focal laser at week 1, and one week after visits at which the participant met laser re-treatment criteria to the end of the study (week 52) starting at week 16; laser re- treatment was permitted no more than once every 16 weeks.

    Procedure: Laser Photocoagulation

Interventions

  • ProcedureLaser Photocoagulation

    laser every 16 weeks as needed

    Also known as: macular laser therapy

  • Also known as: IAI; EYLEA®; BAY86-5321; VEGF Trap-Eye

06

What researchers measure

Primary outcomes

  1. Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF)

    Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Measurements were taken at every study visit. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).

    Time frame: At week 24

Secondary outcomes

  1. Change in BCVA From Baseline to Week 52 - LOCF

    Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).

    Time frame: At week 52

  2. Participants With Gains in ETDRS Letter Score of at Least 15 Letters - LOCF

    Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).

    Time frame: At week 24 and week 52

  3. Change From Baseline in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) - LOCF

    Retinal thickness was evaluated using OCT at every visit except week 1. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).

    Time frame: At week 24 and week 52

  4. Number of Focal Laser Treatments

    Time frame: Week 1 to week 48

07

Results

Posted Sep 9, 2014

Participant flow

A total of 221 participants were randomized at 39 sites in the US, Canada, and Austria. After the 1 year treatment period, participants were to be followed for safety in a 6 mo. follow-up phase. The last visit for this study occurred in September, 2010.

Participant flow — Overall Study
MilestoneLaser PhotocoagulationIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN
Started4444444445
Participants received treatment4444444245
Completed3338333438
Not completed11611107
Withdrew: Withdrawal by subject21323
Withdrew: Protocol violation10010
Withdrew: Adverse event33100
Withdrew: Death11220
Withdrew: Lost to follow-up01424
Withdrew: Lack of efficacy20000
Withdrew: Other20130

Outcome measures

PrimaryChange in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF)

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Measurements were taken at every study visit. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).

Time frame:
At week 24
Reported as:
Mean · letters correctly read
Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF)
letters correctly readLaser PhotocoagulationIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN
Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF)2.5 ± 16.148.6 ± 14.6411.4 ± 8.678.5 ± 7.5010.3 ± 7.52
SecondaryChange in BCVA From Baseline to Week 52 - LOCF

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).

Time frame:
At week 52
Reported as:
Mean · letters correctly read
Change in BCVA From Baseline to Week 52 - LOCF
letters correctly readLaser PhotocoagulationIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN
Change in BCVA From Baseline to Week 52 - LOCF-1.3 ± 20.7211.0 ± 15.4013.1 ± 10.549.7 ± 8.9312.0 ± 11.09
SecondaryParticipants With Gains in ETDRS Letter Score of at Least 15 Letters - LOCF

Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).

Time frame:
At week 24 and week 52
Reported as:
Number · participants
Participants With Gains in ETDRS Letter Score of at Least 15 Letters - LOCF
participantsLaser PhotocoagulationIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN
At week 249 ± 135.1715 ± 110.6514 ± 143.047 ± 141.7812 ± 132.17
At week 52518201019
SecondaryChange From Baseline in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) - LOCF

Retinal thickness was evaluated using OCT at every visit except week 1. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).

Time frame:
At week 24 and week 52
Reported as:
Mean · microns
Change From Baseline in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) - LOCF
micronsLaser PhotocoagulationIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN
At week 24-67.9 ± 135.17-144.6 ± 110.65-194.5 ± 143.04-127.3 ± 141.78-153.3 ± 132.17
At week 52-58.4 ± 177.60-165.4 ± 135.72-227.4 ± 148.96-187.8 ± 135.01-180.3 ± 124.43
SecondaryNumber of Focal Laser Treatments
Time frame:
Week 1 to week 48
Reported as:
Mean · Treatments
Number of Focal Laser Treatments
TreatmentsLaser PhotocoagulationIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN
Number of Focal Laser Treatments2.5 ± 0.870.8 ± 0.930.5 ± 0.660.8 ± 0.860.7 ± 0.77

Adverse events

Collected over Day 1 to week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Laser Photocoagulation—10/44 (22.7%)20/44 (45.5%)
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4—14/44 (31.8%)22/44 (50%)
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4—13/44 (29.5%)22/44 (50%)
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8—12/42 (28.6%)26/42 (61.9%)
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN—6/45 (13.3%)24/45 (53.3%)
Most frequent serious events
Showing 10 of 109
Most frequent serious events
EventLaser PhotocoagulationIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN
Cardiac failure congestiveCardiac disorders0/440/443/441/422/45
CellulitisInfections and infestations0/443/442/440/421/45
Vitreous haemorrhageEye disorders3/440/440/440/420/45
Chest painGeneral disorders0/440/442/440/423/45
DehydrationMetabolism and nutrition disorders0/440/440/442/420/45
Vitreous haemorrhageEye disorders1/441/441/442/420/45
AnaemiaBlood and lymphatic system disorders0/441/442/440/420/45
Cerebrovascular accidentNervous system disorders1/441/442/440/420/45
HyperglycaemiaMetabolism and nutrition disorders0/440/442/440/420/45
HypertensionVascular disorders0/440/442/441/420/45
Most frequent other events
Showing 10 of 50
Most frequent other events
EventLaser PhotocoagulationIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN
Conjunctival haemorrhageEye disorders8/4412/447/4415/4213/45
Eye painEye disorders2/446/445/446/427/45
Blood glucose increasedInvestigations1/444/443/446/426/45
HypertensionVascular disorders5/445/445/446/425/45
Glycosylated haemoglobin increasedInvestigations2/446/445/445/422/45
Intraocular pressure increasedInvestigations1/446/446/445/422/45
Ocular hyperaemiaEye disorders2/445/442/443/423/45
Vitreous detachmentEye disorders5/443/443/443/420/45
Vitreous floatersEye disorders2/445/443/442/422/45
Vitreous haemorrhageEye disorders5/443/445/444/423/45

Baseline characteristics

Full analysis set (FAS): included all randomized patients who received any study drug, had baseline assessments, and had at least one (1) post-baseline assessment.

Age, Continuous
Age, Continuous(years)Laser PhotocoagulationIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRNTotal
Mean64.0 ± 8.1262.3 ± 10.7062.1 ± 10.5062.5 ± 11.4960.7 ± 8.6662.3 ± 9.92
Sex: Female, Male
Sex: Female, Male(Participants)Laser PhotocoagulationIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRNTotal
Female172017201690
Male2724272229129
08

Study locations

47 sites
  • Artesia, California 90701, United States
  • Beverly Hills, California 90211, United States
  • Mountain View, California 94040, United States
  • Pasadena, California 91105, United States
  • Sacramento, California 95819, United States
  • Santa Ana, California 92705, United States
  • Hamden, Connecticut 06518, United States
  • New London, Connecticut 06320, United States
  • Boynton Beach, Florida 33426, United States
  • Fort Lauderdale, Florida 33334, United States
  • Fort Myers, Florida 33912, United States
  • Ocala, Florida 34474, United States
  • Palm Beach Gardens, Florida 33410, United States
  • Winter Haven, Florida 33880, United States
  • Augusta, Georgia 30909, United States
  • Honolulu, Hawaii 96815, United States
  • Indianapolis, Indiana 46280, United States
  • Bangor, Maine 04401, United States
  • Baltimore, Maryland 21287, United States
  • Boston, Massachusetts 02114, United States
  • Jackson, Michigan 48104, United States
  • Kansas City, Missouri 64108, United States
  • Lincoln, Nebraska 68506, United States
  • New Brunswick, New Jersey 08901, United States
  • Northfield, New Jersey 08225, United States
  • Toms River, New Jersey 08753, United States
  • Rochester, New York 14620, United States
  • Charlotte, North Carolina 28210, United States
  • Raleigh, North Carolina 27607, United States
  • Cincinnati, Ohio 45243, United States
  • Pittsburgh, Pennsylvania 15213, United States
  • Greenville, South Carolina 29605, United States
  • West Columbia, South Carolina 29169, United States
  • Nashville, Tennessee 37203, United States
  • Abilene, Texas 79606, United States
  • Arlington, Texas 76012, United States
  • Austin, Texas 78705, United States
  • Houston, Texas 77030, United States
  • McAllen, Texas 78503, United States
  • San Antonio, Texas 78215, United States
  • San Antonio, Texas 78240, United States
  • Salt Lake City, Utah 84107, United States
  • Wien, 1090, Austria
  • Vancouver, British Columbia V5Z 3N9, Canada
  • Victoria, British Columbia V8V 4X3, Canada
  • London, Ontario N6A 4G5, Canada
  • Mississauga, Ontario L4W 1W9, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Dec 2009 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 4 years 9 months after primary completion. A results delay was requested in Apr 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2008
First posted
Nov 11, 2008
Start
Dec 2008
Primary completionActual
Dec 2009
CompletionActual
Sep 2010
Results delay requested
Apr 19, 2011
Results first posted
Sep 9, 2014
Last update
Sep 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00789477
Collaborators
Bayer
Responsible party
Sponsor
First posted
Nov 11, 2008
Start date
Dec 2008
Primary completion
Dec 2009
Completion
Sep 2010
Results posted
Sep 9, 2014
Last update
Sep 9, 2014

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion